[Evaluation of the efficacy of a comprehensive programme of secondary prevention of cardiovascular disease in primary care: the PREseAP Study].
To assess the efficacy of a comprehensive secondary prevention programme to reduce morbidity and mortality in patients who have suffered a cardiovascular (CV) event; to control CV risk factors and prophylactic treatment in order to prevent recurrence; and to improve the quality of life of patients with cardiovascular disease. Randomised, pragmatic, open clinical trial in primary care. A total of 42 primary care centres of 8 different areas in Spain. Men and women below 86 years old, diagnosed with coronary disease and/or stroke and/or peripheral vascular disease in the preceding year, and who have no serious or terminal disease. Primary care centres will be randomised to following usual care (control group), or to following a comprehensive programme of secondary prevention (intervention group). Cardiovascular fatal events, cardiovascular non-fatal events, total mortality and health-related quality of life (SF-36).